AZGP1 and Parkinson disease: The observed tissue-specific glycosylation variations,particularly the increased fucosylation in saliva and altered glycosylationof AZGP1 across all biofluids, suggest that these changes reflectsystemic pathological processes beyond the central nervous systemand offer promising avenues for targeted biomarker discovery and understandingthe diverse pathophysiological mechanisms of PD.